Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease☆

[1]  A. Smith,et al.  The vitamin D receptor gene is associated with Alzheimer's disease , 2011, Neuroscience Letters.

[2]  S. Kreiner,et al.  No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. , 2011, Kidney international.

[3]  D. Eyles,et al.  Vitamin D insufficiency is associated with impaired vascular endothelial and smooth muscle function and hypertension in young rats , 2011, The Journal of physiology.

[4]  P. Houillier,et al.  Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  S. Pilz,et al.  Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  R. St-Arnaud,et al.  Differential Effects of Oral Doxercalciferol (Hectorol®) or Paricalcitol (Zemplar®) in the Cyp27b1-Null Mouse Model of Uremia , 2011, Nephron Experimental Nephrology.

[7]  B. Horne,et al.  Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? , 2011, American heart journal.

[8]  A. Dusso,et al.  Vitamin D in chronic kidney disease. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[9]  S. Dankel,et al.  Primary Hyperparathyroidism Influences the Expression of Inflammatory and Metabolic Genes in Adipose Tissue , 2011, PloS one.

[10]  É. Dewailly,et al.  Dairy Product Intake and Its Association with Body Weight and Cardiovascular Disease Risk Factors in a Population in Dietary Transition , 2011, Journal of the American College of Nutrition.

[11]  H. DeLuca,et al.  The importance of stereochemistry on the actions of vitamin D. , 2011, Current topics in medicinal chemistry.

[12]  W. C. O'Neill,et al.  Treatment with pyrophosphate inhibits uremic vascular calcification. , 2011, Kidney international.

[13]  W. Johnson,et al.  Prediabetes and Prehypertension in Healthy Adults Are Associated With Low Vitamin D Levels , 2011, Diabetes Care.

[14]  Gavin Giovannoni,et al.  A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. , 2010, Genome research.

[15]  S. Radhakrishnan,et al.  Myocardial dysfunction due to hypocalcemia , 2010, Indian pediatrics.

[16]  J. W. Kim,et al.  Dysregulation of renal vitamin D metabolism in the uremic rat. , 2010, Kidney international.

[17]  R. Lucas,et al.  Assessing vitamin D status: pitfalls for the unwary. , 2010, Molecular nutrition & food research.

[18]  S. Heikkinen,et al.  The down-regulation of the human MYC gene by the nuclear hormone 1alpha,25-dihydroxyvitamin D3 is associated with cycling of corepressors and histone deacetylases. , 2010, Journal of molecular biology.

[19]  M. Tokumoto,et al.  Myocardial effects of VDR activators in renal failure , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  S. Mihaila.  Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. , 2010, Maedica.

[21]  M. Kumari,et al.  1,25-Dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: A pilot feasibility study , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  D. Spizzichino,et al.  Risk factors of one year increment of coronary calcifications and survival in hemodialysis patients , 2010, BMC nephrology.

[23]  C. Gadegbeku,et al.  Relationship of vitamin D and parathyroid hormone with obesity and body composition in African Americans , 2010, Clinical endocrinology.

[24]  M. Nakane,et al.  Vitamin D Receptor Activation Mitigates the Impact of Uremia on Endothelial Function in the 5/6 Nephrectomized Rats , 2010, International journal of endocrinology.

[25]  P. Ponikowski,et al.  Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative , 2009, European heart journal.

[26]  P. Donnan,et al.  Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS) , 2009, Clinical endocrinology.

[27]  D. Fliser,et al.  Clinical relevance of FGF-23 in chronic kidney disease. , 2009, Kidney international. Supplement.

[28]  L. Gianotti,et al.  Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[29]  Hyoung-Gon Lee,et al.  Cell Cycle Re-Entry and Mitochondrial Defects in Myc-Mediated Hypertrophic Cardiomyopathy and Heart Failure , 2009, PloS one.

[30]  J. Eisman,et al.  Global vitamin D status and determinants of hypovitaminosis D , 2009, Osteoporosis International.

[31]  C. Held,et al.  Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community , 2009, Circulation.

[32]  Z. Massy,et al.  Vitamin D affects survival independently of vascular calcification in chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[33]  M. Budoff,et al.  Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[34]  Michelle Chan,et al.  Lean phenotype and resistance to diet-induced obesity in vitamin D receptor knockout mice correlates with induction of uncoupling protein-1 in white adipose tissue. , 2009, Endocrinology.

[35]  Zhongyi Zhang,et al.  Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. , 2008, Kidney international.

[36]  S. Greenland,et al.  Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[37]  N. Wareham,et al.  Baseline Serum 25-Hydroxy Vitamin D Is Predictive of Future Glycemic Status and Insulin Resistance , 2008, Diabetes.

[38]  A. Zambrano,et al.  Vitamin D-Dependent Recruitment of Corepressors to Vitamin D/Retinoid X Receptor Heterodimers , 2008, Molecular and Cellular Biology.

[39]  Michael J. Pencina,et al.  Vitamin D Deficiency and Risk of Cardiovascular Disease , 2008, Circulation.

[40]  R. Zahradnik,et al.  Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis. , 2007, Kidney international.

[41]  N. Bodyak,et al.  Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals , 2007, Proceedings of the National Academy of Sciences.

[42]  L. Hamm,et al.  Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis or Peritoneal Dialysis , 2007, American Journal of Nephrology.

[43]  S. Sprague.  Mortality risk among hemodialysis patients receiving different vitamin D analogs. , 2007, Kidney international.

[44]  J. Zanchetta,et al.  Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis , 2007, Hemodialysis international. International Symposium on Home Hemodialysis.

[45]  R. Simpson,et al.  Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[46]  D. Tishkoff,et al.  1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[47]  A. Nangia,et al.  Vitamin D receptor found in human sperm. , 2006, Urology.

[48]  A. Negri.  Proximal tubule endocytic apparatus as the specific renal uptake mechanism for vitamin D‐binding protein/25‐(OH)D3 complex (Review Article) , 2006, Nephrology.

[49]  E. Bedrick,et al.  Mortality risk among hemodialysis patients receiving different vitamin D analogs. , 2006, Kidney international.

[50]  M. Budoff,et al.  Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. , 2006, Kidney international.

[51]  K. Aihara,et al.  [Vitamin D-vitamin D receptor system regulates antithrombogenicity in vivo]. , 2006, Clinical calcium.

[52]  A. Remaley,et al.  The prevalence of hypovitaminosis D and secondary hyperparathyroidism in obese Black Americans , 2006, Clinical endocrinology.

[53]  Kathryn A. O’Donnell,et al.  Myc Stimulates Nuclearly Encoded Mitochondrial Genes and Mitochondrial Biogenesis , 2005, Molecular and Cellular Biology.

[54]  M. Maurer,et al.  Arterial stiffness in mild primary hyperparathyroidism. , 2005, The Journal of clinical endocrinology and metabolism.

[55]  M. Hernán,et al.  Activated injectable vitamin D and hemodialysis survival: a historical cohort study. , 2005, Journal of the American Society of Nephrology : JASN.

[56]  B. Boucher,et al.  Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. , 2004, The American journal of clinical nutrition.

[57]  V. Andreucci,et al.  Coronary artery calcification in patients with CRF not undergoing dialysis. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[58]  K. Martin,et al.  Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. , 2004, Seminars in nephrology.

[59]  A. Uitterlinden,et al.  Genetics and biology of vitamin D receptor polymorphisms. , 2004, Gene.

[60]  Yoko Yamamoto,et al.  Disruption of Nuclear Vitamin D Receptor Gene Causes Enhanced Thrombogenicity in Mice* , 2004, Journal of Biological Chemistry.

[61]  M. Saad,et al.  Hypovitaminosis D is associated with insulin resistance and β cell dysfunction , 2004 .

[62]  D. Goldsmith,et al.  Cardiac calcification in renal patients: what we do and don't know. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[63]  M. Wolf,et al.  Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. , 2003, The New England journal of medicine.

[64]  K. Hruska,et al.  BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. , 2003, Journal of the American Society of Nephrology : JASN.

[65]  N. Powe,et al.  Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. , 2002, Journal of the American Society of Nephrology : JASN.

[66]  T. Willnow,et al.  Pathways for kidney-specific uptake of the steroid hormone 25-hydroxyvitamin D3 , 2002, Current opinion in lipidology.

[67]  D. Batlle,et al.  Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[68]  F Llach,et al.  Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[69]  H. Minne,et al.  Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. , 2001, The Journal of clinical endocrinology and metabolism.

[70]  J. Cockcroft,et al.  Augmentation of central arterial pressure in mild primary hyperparathyroidism. , 2000, The Journal of clinical endocrinology and metabolism.

[71]  J. H. Green,et al.  Blood pressure responses to high‐calcium skim milk and potassium‐enriched high‐calcium skim milk , 2000, Journal of hypertension.

[72]  J. Rastad,et al.  Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. , 1999, Surgery.

[73]  T. B. Paiva,et al.  Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine. , 1999, Hypertension.

[74]  P. Lips,et al.  An International Comparison of Serum 25-Hydroxyvitamin D Measurements , 1999, Osteoporosis International.

[75]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[76]  A. Díez-Pérez,et al.  Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure. , 1998, The American journal of medicine.

[77]  Arya M. Sharma,et al.  Ultraviolet B and blood pressure , 1998, The Lancet.

[78]  M. Haussler,et al.  The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[79]  P. Froom,et al.  Association of calcitriol and blood pressure in normotensive men. , 1997, Hypertension.

[80]  J. Welsh,et al.  Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant. , 1997, Endocrinology.

[81]  N. Weigel,et al.  1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. , 1997, Endocrinology.

[82]  T. M. Nguyen,et al.  Evidence for a vitamin D paracrine system regulating maturation of developing rat lung epithelium. , 1996, The American journal of physiology.

[83]  J. Wu,et al.  1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. , 1996, The Journal of clinical investigation.

[84]  E. Zeitler,et al.  Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[85]  H. Kronenberg,et al.  Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid x receptor. , 1996, Molecular endocrinology.

[86]  M. Langman,et al.  Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid. , 1996, Cancer research.

[87]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[88]  L. Lind,et al.  Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. , 1995, American journal of hypertension.

[89]  T. O’Connell,et al.  1,25-Dihydroxyvitamin D3 regulation of myocardial growth and c-myc levels in the rat heart. , 1995, Biochemical and biophysical research communications.

[90]  J. Lemire.  Immunomodulatory actions of 1,25-Dihydroxyvitamin D3 , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[91]  J. Reichrath,et al.  Hair follicle expression of 1,25‐dihydroxyvitamin D3 receptors during the murine hair cycle , 1994, The British journal of dermatology.

[92]  M. Rizk-Rabin,et al.  Synthesis of and response to 1,25 dihydroxycholecalciferol by subpopulations of murine epidermal keratinocytes: Existence of a paracrine system for 1,25 dihydroxycholecalciferol , 1994, Journal of cellular physiology.

[93]  D. Gardner,et al.  Negative regulation of the human atrial natriuretic peptide gene by 1,25-dihydroxyvitamin D3. , 1994, The Journal of biological chemistry.

[94]  T. Stamey,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.

[95]  S. Tebbutt,et al.  Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. , 1992, Gut.

[96]  H. Henry.  Vitamin D hydroxylases , 1992, Journal of cellular biochemistry.

[97]  H. Bidmon,et al.  Vitamin D receptors in heart: Effects on atrial natiuretic factor , 1991, Experientia.

[98]  T. Ogihara,et al.  CALCIUM METABOLISM IN ELDERLY HYPERTENSIVE PATIENTS: POSSIBLE PARTICIPATION OF EXAGGERATED SODIUM, CALCIUM AND PHOSPHATE EXCRETION , 1991, Clinical and experimental pharmacology & physiology.

[99]  E. Burgess,et al.  Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. , 1990, American journal of hypertension.

[100]  E. Slatopolsky,et al.  Combined effects of dexamethasone and 1,25-dihydroxyvitamin D3 on parathyroid hormone secretion in cultured bovine parathyroid cells. , 1989, Endocrinology.

[101]  Y. Yazaki,et al.  Expression of Cellular Oncogenes in the Myocardium During the Developmental Stage and Pressure‐Overloaded Hypertrophy of the Rat Heart , 1988, Circulation research.

[102]  J. Laragh,et al.  Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. , 1986, Annals of internal medicine.

[103]  J. Russell,et al.  Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[104]  H. DeLuca,et al.  Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. , 1979, Science.

[105]  H. Pols,et al.  Vitamin D , 1928, Calcified Tissue International.

[106]  S. Draibe,et al.  Risk factors for hypovitaminosis D in nondialyzed chronic kidney disease patients. , 2012, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[107]  K. Kalantar-Zadeh,et al.  Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[108]  Jonathan,et al.  Results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study) , 2011 .

[109]  P. Ponikowski,et al.  Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). , 2010, Contributions to nephrology.

[110]  J. Eisman,et al.  Global vitamin D status and determinants of hypovitaminosis D , 2009, Osteoporosis International.

[111]  E. Krieger,et al.  Vascular changes in chronic renal disease patients with secondary hyperparathyroidism. , 2007, Journal of nephrology.

[112]  S. Durham,et al.  Measurement of vitamin D status: background, clinical use, and methodologies. , 2006, Clinical laboratory.

[113]  N. Kagawa,et al.  Metabolism of vitamin D3 by cytochromes P450. , 2005, Frontiers in bioscience : a journal and virtual library.

[114]  J. Aloia,et al.  Body fat content and 25-hydroxyvitamin D levels in healthy women. , 2003, The Journal of clinical endocrinology and metabolism.

[115]  R. Bouillon.  Vitamin D: From Photosynthesis, Metabolism, and action to Clinical Applications , 2001 .

[116]  T. Louis,et al.  Effect of calcium supplementation on serum cholesterol and blood pressure. A randomized, double-blind, placebo-controlled, clinical trial. , 2000, Archives of family medicine.

[117]  K. Hiramori,et al.  Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. , 1999, Internal medicine.

[118]  C. Park,et al.  Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[119]  C. Bell,et al.  Ultraviolet light may contribute to geographic and racial blood pressure differences. , 1998, Hypertension.

[120]  N. Weigel,et al.  1 , 25-Dihydroxyvitamin D 3 and 9-cis-Retinoic Acid Act Synergistically to Inhibit the Growth of LNCaP Prostate Cells and Cause Accumulation of Cells in G 1 * , 1997 .

[121]  S. Manolagas,et al.  Vitamin D and the hematolymphopoietic tissue: a 1994 update. , 1994, Seminars in nephrology.

[122]  L. Lind,et al.  Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. , 1989, American journal of hypertension.

[123]  B. Nadal-Ginard,et al.  Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[124]  M. Haussler,et al.  Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. , 1987, The Journal of clinical endocrinology and metabolism.